Search

everythinglearnresearchcommunity

for

Search:↓

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

Mycophenolate mofetil effectively improved skin pigmentation and itching in a woman with lichen planus pigmentosus and frontal fibrosing alopecia.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

A woman's shingles infection triggered her first episode of a rare neurological disorder and blood vessel inflammation.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

Ustekinumab treatment didn't prevent frontal fibrosing alopecia.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Apremilast did not work for treating severe alopecia areata.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.